Will kinase inhibitors have a dark side?

doi:10.1056/NEJMcibr062354

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Will kinase inhibitors have a dark side?

The New England journal of medicine - 20 Jul 2006

Sawyers Charles L

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Mice
Share to Mutation
Share to Neoplasm Metastasis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasms

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-akt

Share to Receptor, ErbB-2

Source

Open in PubMed

Identifiers

PMID: 16855275
DOI: 10.1056/NEJMcibr062354

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Will kinase inhibitors have a dark side?PMID 16855275Read ↗

Do fourth-generation EGFR inhibitors showcase the future of kinase inhibitors?Semantic proximity Read ↗

Role and mechanistic actions of protein kinase inhibitors as an effective drug target for cancer and COVIDSemantic proximity Read ↗

A New Challenging and Promising Era of Tyrosine Kinase InhibitorsSemantic proximity Read ↗

Imatinib: the promise of a "magic bullet" for cancer fulfilled.Semantic proximity Read ↗

Polypharmacology is an enduring and nearly universal property of kinase inhibitorsSemantic proximity Read ↗

PARP inhibitors coming of ageSemantic proximity Read ↗

EMBRACing a new PARP inhibitor?Semantic proximity Read ↗

[Kinase inhibitors].Semantic proximity Read ↗

Recent advances in the rational design and development of LIM kinase inhibitors are not enough to enter clinical trialsSemantic proximity Read ↗

Cell biology. Lessons in rational drug design for protein kinases.Semantic proximity Read ↗

PARP inhibitors: the story is still unfolding.Semantic proximity Read ↗

Small molecule PIKfyve inhibitors as cancer therapeutics: Translational promises and limitationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.